Nature Publishing Group Jan 2005 - Mar 2009
Editor Assistant, Gene Therapy
University of Pittsburgh Jan 2005 - Mar 2009
Assistant Professor
Massachusetts General Hospital Apr 2001 - Dec 2004
Post-Doc
Cold Genesys
Chief Strategy Officer
Revitope
Consultant
Oncorus Jan 2017 - Jan 2018
Director Immunology and Virology
Oncorus Jan 2016 - Jan 2018
Scientific Founder Oncorus
University of Pittsburgh School of Medicine Apr 2005 - Dec 2016
Assistant Professor and Reseach Associate, Neurological Surgery and Molecular Genetics and Biochemistry
Education:
Harvard Medical School
Università Degli Studi Di Ferrara
Doctorates, Doctor of Philosophy, Biochemistry, Philosophy
Università Degli Studi Di Ferrara
Master of Science, Masters, Genetics
Babson College
Master of Business Administration, Masters
Skills:
Tumor Immunology Oncolytic Vectors Strategic Planning Cell Biology Research Cross Functional Team Leadership Managing Partner Relationships Clinical Research Pre Clinical Studies Immunology Cancer Immunotherapy Viral Vectors Drug Discovery Clinical Study Design Collaborative R&D Infectious Diseases Molecular Pharmacology Safety Pharmacology Cell Lines Mirna Immunocytochemistry Animal Models Virology Molecular Virology Molecular Genetics Molecular Biology Product Validation Cell Culture Development Stem Cells Data Analysis Cancer Cancer Biology Biotechnology In Vivo Cancer Research Oncology Biochemistry Strategy Life Sciences Biomarkers Clinical Development Business Strategy Strategic Communications Interpersonal Skills Initiation
- Pittsburgh PA, US Justus B. Cohen - Allison Park PA, US Paola Grandi - Pittsburgh PA, US
Assignee:
University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
A61K 35/763 C07K 14/005 C12N 7/00
Abstract:
The present invention provides a recombinant herpes simplex virus (HSV), comprising (a) a mutation of the glycoprotein B (gB) at position 285 or 549, (b) a plurality of copies of one or more microRNA target sequences inserted into a locus of an HSV gene required for HSV replication, wherein said target sequence is the reverse complement of microRNA miR-124 and wherein said target sequence is present in the ICP4 gene, and (c) a transgene encoding a matrix metalloproteinase. The present invention also provides a method of killing a cancerous cell using a recombinant HSV according to the invention and a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a recombinant HSV according to the invention.
- Pittsburgh PA, US Justus B. Cohen - Allison Park PA, US Paola Grandi - Pittsburgh PA, US
International Classification:
A61K 35/763 C07K 14/005 C12N 7/00
Abstract:
The present invention provides a recombinant herpes simplex virus (HSV), comprising (a) a mutation of the glycoprotein B (gB) at position 285 or 549, (b) a plurality of copies of one or more microRNA target sequences inserted into a locus of an HSV gene required for HSV replication, wherein said target sequence is the reverse complement of microRNA miR-124 and wherein said target sequence is present in the ICP4 gene, and (c) a transgene encoding a matrix metalloproteinase. The present invention also provides a method of killing a cancerous cell using a recombinant HSV according to the invention and a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a recombinant HSV according to the invention.
- Pittsburgh PA, US Justus B. Cohen - Allison Park PA, US Paola Grandi - Pittsburgh PA, US
International Classification:
A61K 35/763 C12N 7/00
Abstract:
The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.
- Pittsburgh PA, US Justus B. COHEN - Allison Park PA, US Paola GRANDI - Pittsburgh PA, US
International Classification:
A61K 35/763 C12N 7/00
Abstract:
The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.
Googleplus
Paola Grandi
Work:
COMMERCIALISTA
About:
ODIO L'IPOCRISIA
Tagline:
VIVI E LASCIA VIVERE
Bragging Rights:
ARRIVARE A FINE MESE
Paola Grandi
Work:
Atelier "Orto della Vecchia Strega" - Titolare unico
Paola Grandi
Paola Grandi
Paola Grandi
Paola Grandi
Paola Grandi
Work:
University of Pittsburgh Medical Center
Education:
University of Ferrara
Relationship:
Married
Youtube
Stairbook - Chapter 5 - La maschera della gra...
Sandro Gros-Pietro intervista Paola Grandi, autrice del libro "La masc...
Duration:
19m 14s
PAOLA CORTELLESI a casa dei Me contro Te
*SEGUICI SU INSTAGRAM!* ME CONTRO TE (@mecontrote) SOF (@sofi.scali...
Duration:
2m 37s
Gianna Nannini, Emma & Irene Grandi - I Masch...
Il progetto nato da un'ideadiLoredan... Bert (in occasione dei suoi ...
Duration:
4m 18s
Paola Giovetti: "Assagioli e i grandi iniziat...
Conferenza tenutasi a Conegliano, il 10 ottobre 2015, a cura dell'Isti...